calyptelifesciences.com

Calypte Life Sciences, a part of Calypte Biomedical Corporation, offers a broad range of recombinant proteins and antigens as well as proprietary reagents, buffers, and other specialty products to researchers working on immunodiagnostic applications. Our unique products are based on technologies developed by Calypte scientists and are used throughout our range of proven in vitro diagnostic tests.

Founded in 1988, Calypte Biomedical Corporation has a long history of making diagnostic assays for challenging in vitro applications. Calypte is a pioneer in non-blood-based HIV antibody testing and is the first and only company to earn approval from the U.S. Food and Drug Administration for a urine-based HIV-1 antibody screening test and supplemental Western blot. Today, our Aware™ family of rapid oral fluid, blood and urine tests offers unrivalled HIV-1/2 testing flexibility in a non-laboratory setting.

Calypte is also the licensed manufacturer of a unique, quantitative enzyme immunoassay developed by the U.S. Centers for Disease Control and Prevention (CDC) that can discriminate between recent and established HIV-1 infections. Designed for use in epidemiology, the Aware™ BED™ EIA is the most cost effective method for developing accurate HIV-1 incidence estimates. Since its introduction in 2004, the Aware™ BED™ EIA has gained widespread favor with government institutions and HIV intervention programs worldwide, including the US Surveillance National Surveillance System since 2005.

The products we feature in our Life Sciences catalog draw on our years of experience in working with diagnostic systems. We also operate a state-of-the-art facility that is ISO13485 certified where we can scale up manufacturing of any of our products to commercial levels under GMP.

Click here to go to our corporate website and to learn more about Calypte Biomedical Corporation.